查詢結果分析
相關文獻
- Epoietin-induced Antibody-mediated Pure Red Cell Aplasia and Responses to Immunosuppression Therapy: 2 Case Reports and Literature Review
- 紅血球生成素引起之抗體導致的純紅血球再生不良:一病例報告
- 紅血球生成素1998
- The Effect of Recombinant Human Erythropoietin in Treating the Anemia of Prematurity
- The Clinical Experience of Higher rHuEPO Dosage in Chronic Hemodialysis Patients with Epo-Hyporesponsiveness
- Serum Transferrin Receptor is a Good Index of Erythropoietin Treatment in ESRD
- Assessment of Serum Erythropoietin Level in Chronic Hemodialysis Patients
- 降低血液透析病患紅血球生成素使用之改善專案
- The Response to Erythropoietin in Hemodialysis Patients with Thalassemia Diagnosed by Genomic DNA Analysis
- The Early Use of Recombinant Human Erythropoietin in Anemia of Prematurity
頁籤選單縮合
題名 | Epoietin-induced Antibody-mediated Pure Red Cell Aplasia and Responses to Immunosuppression Therapy: 2 Case Reports and Literature Review=紅血球生成素引起之抗體導致的純紅血球再生不良以及用免疫抑制療法有效的治療此疾病:二則病例報告以及文獻回顧 |
---|---|
作者姓名(中文) | 張園鑫; 林建鴻; 林信昌; 張明志; 陳功深; 謝瑞坤; | 書刊名 | 內科學誌 |
卷期 | 21:6 2010.12[民99.12] |
頁次 | 頁441-447 |
分類號 | 415.513 |
關鍵詞 | 紅血球生成素; 純紅血球再生不良; 貧血; 免疫抑制療法; Pure red cell aplasia; Anti-erythropoietin antibodies; Immunosuppression therapy; Dialysis; Erythropoietin; Uremia; |
語文 | 英文(English) |
中文摘要 | 基因重組人類紅血球生成素所引起之純紅血球再生不良是一種罕見疾病,在此我們報告 馬偕醫院確診的2 個基因重組人類紅血球生成素所引起之純紅血球再生不良的病例。病例一 為一位五十三歲尿毒症並接受規則洗腎的女性,平時接受規律的紅血球生成素a(Eprex) 皮 下注射。在Eprex 使用13 個月後病人被發現有不明原因且逐漸惡化的貧血。骨髓抽吸檢查 顯示紅血球系列再生不良,且符合純紅血球再生不良的診斷。抗紅血球生成素抗體亦被偵測 出。在停用Eprex 且使用環孢靈治療後,病人的貧血逐漸改善。且病人血液中亦偵測不到抗 紅血球生成素抗體。之後給病人使用另一種類的紅血球生成素(darbepoetin) 治療。病人最後 貧血完全復原。病例二是一位46 歲的男性,因慢性腎病引起的貧血接受規則的紅血球生成素 b(Recormon) 皮下注射治療。儘管使用更高劑量的Recormon 以及darbepoetin 治療,他的貧血 卻越來越惡化。病人血液中可偵測到抗紅血球生成素抗體。因此我們停止使用紅血球生成素 以及使用免疫抑制的藥物類固醇和azathioprine 治療。病人貧血逐漸改善而不需要輸血。 |
英文摘要 | Recombinant human erythropoietin (rHuEPO) induced antibody-mediated pure red cell aplasia (PRCA) was a rare disease. Herein, we reported 2 cases with confirmed diagnosis of EPO- induced antibodymediated PRCA in our institution. Case 1: a 53 year-old female with uremia and regular hemodialysis was regularly administered with EPO-α (Eprex) subcutaneously. Progressive unexplained anemia was noted 13 months after therapy with Eprex. Bone marrow study revealed remarkable erythroid hypoplasia compatible with PRCA. Anti-EPO antibody levels were detected. After withdrawal of Eprex and administration of cyclosporine, her anemia gradually improved. Serum level of anti-EPO antibody became undetectable. Another form of EPO (darbepoetin) was administered to the patient and hemoglobin recovered to 10.4 g/dL. Case 2: a 46 year-old male with chronic kidney disease related anemia underwent a regular subcutaneous EPO-β (Recormon) therapy. He developed profound anemia in spite of dose increase of EPO-β and combination with darbepoetin usage. EPO induced antibody-mediated PRCA was confirmed by the detection of anti-EPO antibody and severe erythroid hypoplasia in the bone marrow. Cessation of EPO and initiation of immunosuppression therapy with methylprednisolone and azathioprine were instituted. The patient finally became transfusion-independent. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。